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1. BACKGROUND 
Idiopathic pulmonary fibrosis (IPF) is an interstitial 
chronic pulmonary disease, which affect patients older 
than 50 years old. Disease aetiology is unknown, but has 
been associated with risk factors such as tobacco 
consumption, viral infections, environmental pollution, 
drug and genetic predisposition (1-2). Estimated incidence 
varies between 7 and 16 cases/100000 inhabitants/year, 
with a prevalence ranging between 14 and 43 
cases/100000 inhabitants (3). 
IPF is characterized by an abnormal histopathological 
mesenchymal cell proliferation, fibrosis, overproduction 
and disorganized collagen deposition, extracellular matrix 
changes with distortion of pulmonary architecture and 
appearance of subpleural cysts (honeycomb cysts), with 
accumulation of myofibroblast and fibroblast (3-5). In 
early stages, clinical pattern is similar to other lung 
diseases; signs and symptoms is unproductive cough, 
fatigue, eosinophilia, clubbing and increased acute phase 
reactants. 
There is no clear consensus about patients’ 
classification. The mild, moderate and severe terms are 
used depending on symptoms and function tests, although 
only mild-to-moderate IPF has been characterized (Forced 
Vital Capacity (FVC) ≥50%, Diffusion of Carbon Dioxide 
(DLCO) ≥35% (6)). Despite the mild diagnosis, medium-
term prognosis is poor, with a median survival between 
two and four years after diagnosis. Respiratory failure is 
the most common cause of death (40%). Other causes of 
death in patients with IPF include heart failure, ischemic 
heart disease, infection, and pulmonary embolism. Age 
under 50 years, female gender, preserved lung function 
and increased proportion of lymphocytes (20-25%) in 
bronchoalveolar fluid have been associated with more 
survival (7). Age over 70 years, Comorbidities (pulmonary 
hypertension), emphysema and lung cancer), DLCO under 
40%, FVC decrease≥10% and DLCO decrease≥15% 
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(percentage of predicted) at 6-12 months, desaturation 
during (Six Minute Walk Test) 6MWT≤88% and extension 
of the fibrosis in HRCT (High Resolution Computed 
Tomography) were associated with worst prognosis (6).  
The therapeutic approach aims to preserve lung 
function and reduce the inflammatory component of the 
disease. Pirfenidone is an antifibrotic agent that inhibits 
the transforming growth factor beta (TGB-b), increasing 
the synthesis of collagen, decreasing extracellular matrix 
and blocking the proliferation of fibroblasts. It is indicated 
for the treatment of mild-moderate IPF (FVC> 50%, 
DLCO> 35%). The clinical efficacy of pirfenidone has 
been studied in three studies in Phase 3, multicenter, 
randomized, double-blind, placebo-controlled patients with 
IPF, which has shown a 30% improvement versus placebo 
in the FVC (8,9). 
2. OBJECTIVE 
To describe the main clinical outcome in patients mild-
moderate IPF treated with pirfenidona after a year of 
monitoring follow-up the therapeutic protocol stablished in 
the hospital. 
3. METHOD 
When pirfenidone was available for clinical practice in 
our hospital, Pneumolgy and Pharmacy departments 
reached an agreement about the use of pirfenidone, 
demarcating clinical conditions that must be met to start 
the treatment. The pirfenidone-use criteria for a new 
patient was: diagnosis of mild-moderate IPF (forced Vital 
Capacity (FVC) >50% and diffusion of Carbon Dioxide 
(DLCO) >35%, age<80 years, charlson index<3 
(excluding age), absence of severe renal impairment 
(ClCr<30 ml/min), absence of acute liver failure, advanced 
fibrosis, cirrhosis or hepatocellular carcinoma, no 
hypersensitivity to pirfenidone and no significant drug 
interactions (no administered with fluvoxamine, grapefruit 
juice or other inhibitors of cytP4501A2 and rifampicin, 
snuff or other inducers cytP4501A2). Patients starting 
treatment between January and March 2014 were chosen. 
A monitoring program was established during the first year 
of treatment which included lung function and biochemical 
study at months 1, 4, 8 and 12 from the beginning. The 
main clinical outcome was evaluated by the response; at 
month 12 was considered as positive when FVC and 
DLCO were increased from baseline, and was considered 
stable when FVC and/or DLCO do not decrease more than 
10% and 15% from the baseline respectively. Withdrawal 
criteria were established when FVC and/or DLCO were 
reduced more than 10% and 15% respectively (All 
reductions were considered absolute from the baseline 
value). All patients were treated with an oral pirfenidone 
increasing-dose schedule: induction dose of 267 mg (1 
pill) each 8 hours during the first week, 534 mg (2 pill) 
each 8 hours during second week, and maintenance dose of 
801 mg (3 pills) each 8 hours from the third week if 
adequate tolerance. 
From electronic clinical records, were obtained: 
demographic data, FVC, DLCO, date of start of treatment, 
dosage and adverse effects experienced. From pharmacy 
record were obtained dispensed pills. Adherence was 
computed as percentage of dispensed pills with respect to 
theoretical total pills must be taken during follow up 
period. Cost of pirfenidone was calculated as acquisition 
hospital costs at December 31, 2014. 
4. RESULTS 
Ten patients (9 males) with mild IPF met the criteria 
for starting treatment. The mean age was 69.5±5.0 years 
and the average time from diagnosis to starting treatment 
with pirfenidone was 2.7±1.8 years (range 1-7 years). 
Seven patients received N-acetylcysteine as a 
pretreatment. Until the time of marketing, all treatments 
initiated were authorized by the Agencia Española del 
Medicamento (AGEMED) and processed as “foreign 
drugs”. Eight of the ten patients continued on treatment 
until month 12. One patient died a month after starting 
treatment for not related lung pathology reasons. One 
patient discontinued pirfenidona in the eleventh month due 
to adverse effect (severe tremor). According with 
established criteria, 7 patients presented at month twelve a 
positive response, and only one patient did not achieve 
therapeutic targets established (improvement or stability) 
and treatment was changed to nintedanib at 12th month 
from the beginning. Mean baseline of FVC and DLCO 
were 85.3±15.4% and 55.6±16.7% respectively. Figure 1 
compares our population with the results published in the 
clinical trials (8-9); at week 52 (12 months), our patients 
had a mean change in FVC (%) of -2.4±6.9% versus -5.2% 
reported on clinical trials in the pirfenidone group (-8.3% 
with placebo). Table 1 shows FVC and DLCO results at 
12th month and response for each patient. 
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Figure 1. Comparison of mean change in FVC (%) of our sample of patients with clinical trials. 
 
Table 1. FVC and DLCO change from baseline at the end of follow up period (month 12 from start) and response. 
Patient 
number 
change 
FVC(%) 
Change 
DLCO(%) Response at the end of follow up period (12 months) 
1 -7 1 WITHDRAWAL AT 11TH MONTH (ADVERSE EFFECTS: TREMOR) 
2 -13 -11 WITHDRAWAL AT 12TH MONTH. CRITERIA NON COMPLISHED. 
3 -7 -8 POSITIVE RESPONSE 
4 -2 3 POSITIVE RESPONSE 
5 -8 -10 POSITIVE RESPONSE 
6 Not lung-related death 
7 1 -2 POSITIVE RESPONSE 
8 7 -5 POSITIVE RESPONSE 
9 -3 -6 POSITIVE RESPONSE 
10 6 -11 POSITIVE RESPONSE 
 
The most common adverse reactions in our patients 
were nausea 18%, asthenia 22%, dyspepsia 19%, dizziness 
18%, photosensitivity 12% and joint pain 10%; in clinical 
trials were nausea 40%, asthenia 20%, dyspepsia 30%, 
dizziness 40%, photosensitivity 40% and joint pain 10%. 
All patients showed any adverse effect. In all cases were 
mild or moderate severities. Higher incidence of adverse 
effects was observed than clinical trials reported. 
However, none of the patients experienced a significant 
increase of liver enzymes. In four patients pirfenidone 
dose was reduced due to adverse effects (All cases with 
reduction to 534 mg/8hours as maintenance dose); 3 
patients showed gastrointestinal intolerance and 1 patient 
showed photo-toxicity. 
Treatment adherence was 100% according to pharmacy 
records and considering dose reductions. At full dose, cost 
per patient and year was 30563€. Total cost per response 
was 37233€. 
5. DISCUSSION 
Our study population data compared to clinical trials 
show that pirfenidone had an effectiveness about 50% 
higher with a higher incidence of adverse effects than in 
clinical trials which in all cases were mild or moderate 
severities. With our small population study can not be 
compared with the clinical trials, but suggest a good 
handling of the drug by the multidisciplinary clinical team. 
Therefore, pirfenidone showed effectiveness and was well 
tolerated in clinical practice for patients with mild-
moderate IPF within a twelve months follow up period 
where adverse effects can be controlled by dose 
adjustment. However, either in clinical trials or in our 
experience, results cannot be extrapolated to longer 
periods of time according with the course of the illness, 
where final outcome variables as survival, quality of life or 
functional status are more relevant than changes in FVC or 
DLCO. It is also necessary to observe results of 
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effectiveness and toxicity in the longer term. Taking into 
account high cost of pirfenidone, will be necessary 
perform economic evaluations in order to identify those 
patients that reach a greater clinical benefit with the lower 
cost possible. This type of analysis is necessary if we 
consider the availability of alternative therapy (nintedanib) 
for the same clinical objective. 
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